1307381-31-2

Usage

Uses

Given the provided materials, specific uses for Spiro[piperidine-4,7'-[7H]thieno[2,3-c]pyran], 2'-chloro-4',5'-dihydrohave not been detailed. However, based on its potential pharmaceutical applications, we can infer possible areas of use:
Used in Pharmaceutical Industry:
Spiro[piperidine-4,7'-[7H]thieno[2,3-c]pyran], 2'-chloro-4',5'-dihydrocould be utilized as a pharmaceutical agent for [specific medical conditions or treatments], given its unique molecular structure that allows for potential interactions with biological systems. The exact application type and reason would depend on the outcomes of further studies and clinical trials aimed at understanding its bioactivity and safety profile.
Without additional context or data on specific applications, it is not possible to provide more detailed uses for Spiro[piperidine-4,7'-[7H]thieno[2,3-c]pyran], 2'-chloro-4',5'-dihydro-. Its potential applications in different industries would be contingent upon the results of ongoing research into its properties and efficacy.

Upstream product

• 1283095-47-5 4′,5′-dihydrospiro[piperidine-4,7′-thieno[2,3-c]pyran] 
• 41979-39-9 4-piperidone hydrochloride 
• 6964-21-2 thiophen-3-yl-acetic acid 
• 13781-67-4 3-(2-hydroxyethyl)thiophene 
• 1307248-45-8 tert-butyl 2′-chloro-4′,5′-dihydrospiro-[piperidine-4,7′-thieno[2,3-c]pyran]-1-carboxylate 
• 1283095-48-6 tert-butyl-4′,5′-dihydro-1H-spiro[piperidine-4,7′-thieno[2,3-c]pyran]-1-carboxylate 

Downstream Products

• 1378389-67-3 2-(2-chlorophenylmethyl)-3-(2-chlorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)-N,N-dimethylpropanamide 
• 1378390-39-6 tert-butyl 2-[(2-chlorophenyl)methyl]-3-(2-chlorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)propanoate 
• 1378389-70-8 2-(2-chlorophenylmethyl)-3-(2-chlorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)-N-methylpropanamide 
• 1378389-75-3 2-(2-fluorophenylmethyl)-3-(2-chlorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)-N,N-dimethylpropanamide 
• 1378390-41-0 tert-butyl 2-[(2-fluorophenyl)methyl]-3-(2-chlorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)propanoate 
• 1378389-77-5 2-(2-fluorophenylmethyl)-3-(2-chlorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)-N-methylpropanamide 

Relevant academic research and scientific papers

Synthesis of an ORL-1 Receptor Antagonist via a Radical Bromination and Deoxyfluorination to Afford a gem-Difluorospirocycle

The development of a synthesis of an ORL-1 receptor antagonist is described. The key process improvements in the synthetic sequence include a multikilogram bromination process and the development of a convergent coupling strategy. The process improvements resulted in the production of the active pharmaceutical ingredient (API) on a multikilogram scale.

Development of LC-MS/MS-based receptor occupancy tracers and positron emission tomography radioligands for the nociceptin/orphanin FQ (NOP) receptor

Currently, a lack of sufficient tools has limited the understanding of the relationship between neuropsychiatric disorders and the nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor. Herein, we describe the discovery and development of an antagonist NOP receptor occupancy (RO) tracer and a novel positron emission tomography (PET) radioligand suitable to probe the NOP receptor in human clinical studies. A thorough structure-activity relationship (SAR) around the high-affinity 3-(2′-fluoro-4′,5′- dihydrospiro[piperidine-4,7′-thieno[2,3-c]pyran]-1-yl)-2-(2-halobenzyl) -N-alkylpropanamide scaffold identified a series of subnanomolar, highly selective NOP antagonists. Subsequently, these unlabeled NOP ligands were evaluated in vivo by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in rat to determine brain uptake, kinetics and specific binding. (S)-27 was identified as a suitable unlabeled preclinical RO tracer to accurately quantify NOP receptor engagement in rat brain. Three compounds were selected for evaluation in nonhuman primates as PET tracers: (-)-26, (-)-30, and (-)-33. Carbon-11 labeling of (+)-31 yielded [11C]-(S)-30, which exhibited minimal generation of central nervous system (CNS) penetrant radiometabolites, improved brain uptake, and was an excellent PET radioligand in both rat and monkey. Currently [11C]-(S)-30 is being evaluated as a PET radiotracer for the NOP receptor in human subjects.